- 9. Japanese Patent No. 6742991 issued August 19, 2020, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–JP– 09];
- 10. Korean Patent No. 10–2445667 issued September 16, 2022, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–KR–10];
- 11. Mexican Patent No. 375379 issued September 25, 2020, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176– 2014–0–MX–11];
- 12. Saudi Arabian Patent No. 7456 issued January 5, 2021, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–SA–12];
- 13. United States Patent No. 10,174,098 issued January 8, 2019, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E-176-2014-0-US-13];
- 14. Hong Kong Patent No. HK1236203 issued January 8, 2021, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–HK–14];
- 15. United States Patent No. 10,870,687 issued December 22, 2020, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E-176-2014-0-US-15];
- 16. European Patent Application No. 19217074.4 filed December 17, 2019, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–EP–16];
- 17. Australian Patent No. 2019283892 issued May 13, 2021, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–AU–17];
- 18. Japanese Patent No. 6997267 issued December 20, 2021, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–JP–53];
- 19. Saudi Arabian Patent Application No. 520412601 filed August 10, 2020, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–SA–54];
- 20. Hong Kong Patent Application No. 42020020661.3 filed November 24, 2020, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–HK–55]:
- 21. Mexican Patent Application No. MX/a/2020/010035 filed September 24, 2020, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0– MX–56];
- 22. United States Patent No. 11,434,272 issued September 6, 2020,

- entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E-176-2014-0-US-57];
- 23. Australian Patent No. 2021202227 issued February 23, 2023, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–AU–58];
- 24. Chinese Patent Application No. 20210399056.9 filed April 14, 2021, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E-176-2014-0-CN-59];
- 25. Israeli Patent No. 282518 issued July 2, 2022, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–IL–60];
- 26. Hong Kong Patent Application No. 42022046605.6 filed January 19, 2022, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–HK–62];
- 27. Japanese Patent No. 7291196 issued June 6, 2023, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–JP–63];
- 28. Israeli Patent Application No. 290655 filed February 16, 2022, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–IL–64];
- 29. United States Patent Application No. 17/816,496 filed August 1, 2022, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E-176-2014-0-US-65];
- 30. Korean Patent Application No. 2022–7032043 filed September 15, 2022, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–KR–66];
- 31. Australian Patent Application No. 2023200608 filed February 6, 2023, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–AU–01]; and
- 32. Japanese Patent Application No. 2023–091878 filed June 2, 2023, entitled "Anti-Human Papillomavirus 16 E7 T Cell Receptors" [HHS Reference No. E–176–2014–0–JP–01].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the following:

"Development, manufacture and commercialization of autologous T cell therapy products that are genetically engineered to have stable expression of a T cell receptor (TCR) targeting human papillomavirus ("HPV")–16 E7, as claimed in the Licensed Patent Rights, for the treatment of HPV-associated

cancers and premalignant conditions in humans."

The E-176-2014 patent family is primarily directed to an isolated TCR reactive to HPV 16 E7 antigen in the context of HLA-A*02. HPV describes a group of human viruses known to cause malignancy. Of the group, HPV-16 is the most prevalent strain. Approximately 90% of adults are estimated to have been exposed at some point in their lifetime. HPV drives transformation of infected cells through the expression of certain oncoproteins, chiefly E5, E6 and E7. The latter two are constitutively expressed in malignant cells and are necessary to maintain a transformed state, rendering them useful therapeutic targets.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: September 18, 2023.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2023–20487 Filed 9–20–23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Review of Institutional Training Grants (T32) in Digestive Diseases and Nutrition.

Date: October 17, 2023.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tori Stone, Ph.D., Scientific Review Officer, NIDDK/Scientific Review Branch, National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 827–0994, tori.stone@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: September 15, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-20438 Filed 9-20-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Neurological Disorders and Stroke, including consideration of personnel qualifications and

performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

Date: October 17, 2023.

Time: 2:00 p.m. to 5:30 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (Virtual Meeting).

Date: October 23-24, 2023.

Time: October 23, 2023, 8:30 a.m. to 9:00 p.m.; October 24, 2023, 9:00 a.m. to 12:30 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: The Bethesdan Hotel, 8120 Wisconsin Avenue, Bethesda, Maryland 20814 (Hybrid Meeting).

Contact Person: Jeffrey S. Diamond, Ph.D., Scientific Director, c/o Caren Collins, National Institute of Neurological Disorders and Stroke, NIH, Building 35, Room GF–149, Bethesda, MD 20892, 301–435–1896, diamondj@ninds.nih.gov; collinsca@ninds.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: September 15, 2023.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–20420 Filed 9–20–23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIHAI75N93023R00003: Pre-clinical Models of Infectious Diseases— Task Area B.

Date: October 20–23, 2023.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Annie Walker-Abbey, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 20852, 240–627–3390, aabbey@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 18, 2023.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-20493 Filed 9-20-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Human Liver and Human Liver Cells Research Resource.

Date: November 17, 2023.

Time: 12:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707